Understanding The Function Of The CCR7 Chemokine Receptor In Breast Cancer Cells And Tumours.
Funder
National Health and Medical Research Council
Funding Amount
$549,446.00
Summary
As much as 90% of cancer related deaths occur due to the development of metastatic tumours, and to be able to develop efficient therapies for malignant cancers it is necessary to uncover and study in detail the specific characteristics that allow cancer cells to disseminate from the site of primary tumour. Recent work has implicated proteins that regulate cell movment known as chemokines in this process. We wish to identify and understand the mechanisms by which breast cancer cells use chemokine ....As much as 90% of cancer related deaths occur due to the development of metastatic tumours, and to be able to develop efficient therapies for malignant cancers it is necessary to uncover and study in detail the specific characteristics that allow cancer cells to disseminate from the site of primary tumour. Recent work has implicated proteins that regulate cell movment known as chemokines in this process. We wish to identify and understand the mechanisms by which breast cancer cells use chemokines and their receptors, molecules normally employed by blood cells, to promote tumour metastasis to specific anatomical sites with a view to identify novel targets for therapeutic intervention and risk assessment in breast cancerRead moreRead less
The National Centre For Asbestos Related Diseases (NCARD)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The National Centre for Asbestos Related Diseases is a world-leading centre studying the deadly cancers mesothelioma and lung cancer. Our ongoing Centre of Research Excellence program includes research from the development and genetics of asbestos-related cancers, through to new treatments, novel ways of imaging cancer, and the supportive care of people with these cancers. This program will improve the detection, diagnosis, and treatment of mesothelioma and asbestos-related lung cancer.
The Role Of SPARC In Intestinal Extracellular Matrix Changes And Carcinogenesis
Funder
National Health and Medical Research Council
Funding Amount
$526,728.00
Summary
The inflammatory bowel diseases (IBDs), Crohn s disease (CD) and ulcerative colitis (UC), are lifelong, chronic, incurable conditions and the number of patients being diagnosed with these conditions is increasing worldwide. Over recent years there has been the development of new treatments effective in controlling the chronic inflammation of the bowel in many of these patients. There is no evidence, however that these therapies reduce the rate of bowel scarring or the development of bowel cancer ....The inflammatory bowel diseases (IBDs), Crohn s disease (CD) and ulcerative colitis (UC), are lifelong, chronic, incurable conditions and the number of patients being diagnosed with these conditions is increasing worldwide. Over recent years there has been the development of new treatments effective in controlling the chronic inflammation of the bowel in many of these patients. There is no evidence, however that these therapies reduce the rate of bowel scarring or the development of bowel cancer that complicated these conditions. Healing of the bowel inflammation can result in scarring. Whether scarring develops or not hinges on the balance between tissue production and destruction. If production outstrips destruction then scarring may occur, but if this balance can be modified in favour of reduced production then, potentially, healing may proceed without scarring. This project aims to investigate the role of a protein, SPARC, that can regulate scar formation and its interactions with other proteins that can alter scar formation in a mouse model of chronic bowel inflammation. Chronic inflammation of the bowel can also cause the development of colon cancer. Colon cancer is one of the most common cancers in the Australian population. The level of SPARC in the colon cancer at time of initial surgery may predict the risk of disease recurrence. The aim of this study is to determine if SPARC levels can identify those patients at higher risk of cancer recurrence. The role of SPARC will also be examined in a mouse model of colon cancer to determine if increased SPARC levels increased or decrease the rate of cancer growth and its spread.Read moreRead less
THE ROLE OF RESIDENT MAST CELLS IN ISCHAEMIA-REPERFUSION INJURY OF SKELETAL MUSCLE.
Funder
National Health and Medical Research Council
Funding Amount
$226,320.00
Summary
NHMRC 209113 LAY DESCRIPTION Ischaemia reperfusion injury occurs in skeletal muscle when the blood-oxygen supply is cut off (ischaemia) and later restored (reperfusion). If the duration of ischaemia is short some of the muscle survives. However, when blood flow and oxygen are restored the muscle is subjected to more injury, which is thought to be caused by oxygen and-or white blood cells. This type of injury occurs in muscle which has been crushed, limbs that have been broken or traumatized, in ....NHMRC 209113 LAY DESCRIPTION Ischaemia reperfusion injury occurs in skeletal muscle when the blood-oxygen supply is cut off (ischaemia) and later restored (reperfusion). If the duration of ischaemia is short some of the muscle survives. However, when blood flow and oxygen are restored the muscle is subjected to more injury, which is thought to be caused by oxygen and-or white blood cells. This type of injury occurs in muscle which has been crushed, limbs that have been broken or traumatized, in replantation of amputated parts, in transplantation, after some surgical procedures and after microsurgical transfer of muscle. Once established there is no effective treatment. Our experiments show that a particular cell, the mast cell, and a particular molecule, nitric oxide, are involved in causing ischaemia reperfusion injury. However, the extent of their involvement is unknown. In this proposal we will investigate the effect of replacing mast cells into muscles, in a unique variety of mice which normally don t contain mast cells and are resistant to ischaemia reperfusion injury. In one group of mice we will put back normal mast cells and in a second group of mice we will put back mast cells that cannot produce the nitric oxide molecule. These experiments will determine, unambiguously, the extent of involvement of mast cells and mast cell-derived nitric oxide. In the second part of this proposal will carry out a time course study, using pharmacologically induced mast cell degranulation, to determine when the mast cells become injurious to skeletal muscle. These experiments will identify the period during which mast cell behaviour can be modulated in order to protect the muscle from ischaemia reperfusion injury. Determination of the role of mast cells, and an understanding of the timing during which they become injurious would provide a logical basis for optimizing drug therapy in clinical applications of these findings.Read moreRead less